Bavarian Nordic (BAVA.CO)

Executive Summary

Bavarian Nordic is a leading Danish biotechnology company specializing in the development and commercialization of innovative vaccines, with a strong focus on viral vector platforms. The company's flagship product, IMVAMUNE (MVA-BN), is approved for smallpox and monkeypox (Mpox) and has seen increased demand due to global Mpox outbreaks and government stockpiling efforts. Bavarian Nordic also markets travel vaccines, including a cholera vaccine (PXVX0200) and a chikungunya vaccine candidate (CHIKV VLP) that has completed Phase 2 trials. The pipeline includes ongoing studies for MVA-BN in Mpox (Phase 2, NCT06549530, expected completion May 2026) and in neonates (Phase 3, NCT06844500, completion May 2027), as well as earlier-stage oncology vaccines. The company benefits from a strong commercial footprint, with multiple approved products and a growing public health preparedness market. Near-term catalysts include Phase 2 data readouts, regulatory submissions for the chikungunya vaccine, and potential new government contracts for Mpox vaccines. Financially, Bavarian Nordic is publicly traded (BAVA.CO) with a valuation of ~$2.2 billion and a solid balance sheet supported by product revenues. Overall, the company is well-positioned to capitalize on its vaccine expertise and the ongoing focus on pandemic preparedness.

Upcoming Catalysts (preview)

• H1 2026Phase 2 MVA-BN Mpox vaccine trial data readout80% success
• Q4 2026Regulatory submission for CHIKV VLP chikungunya vaccine70% success
• Q3 2026New government contract for Mpox vaccine stockpiling85% success